Tokyo, April 8, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that certain media coverage related to transfer of business of the Chemo-Sero-Therapeutic Research Institute (“Kaketsuken”) by Astellas reported today is not based on information disclosed by Astellas.
Although it is a fact that Astellas is currently discussing with Kaketsuken for the transfer of Kaketsuken’s business to Astellas, there is nothing decided at this moment.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.